{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-168273","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2024-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.561479+00:00","generated_at":"2026-06-01T01:38:11.160668+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tectonic Therapeutics details TX45 Phase 2 trial design for Group 2 PH-HFpEF","bullets":["Phase 2 randomized, placebo-controlled, double-blind trial to start H2 2024 globally (US, Europe, Eastern Europe, Australia).","Trial enriches for patients with PVR >3 on right heart catheterization; ~180 subjects expected.","Subjects randomized 1:1:1 to two TX45 doses or placebo; 24-week treatment plus 8-week follow-up.","Goal: evaluate efficacy in combined pre- and post-capillary PH and whole Group 2 PH-HFpEF population."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-168273","json":"https://secwatch.observer/filing/0001193125-24-168273.json","markdown":"https://secwatch.observer/filing/0001193125-24-168273.md","text":"https://secwatch.observer/filing/0001193125-24-168273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312524168273/0001193125-24-168273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312524168273/d822923d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:38:11.160668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}